TY  - JOUR
AU  - Zhou, Xiaojuan
AU  - Zhou, Laiyan
AU  - Yao, Zhuoran
AU  - Huang, Meijuan
AU  - Gong, Youling
AU  - Zou, Bingwen
AU  - Zhu, Jiang
AU  - Liu, Yongmei
AU  - Peng, Feng
AU  - Zhang, Yan
AU  - Yu, Min
AU  - Li, Yanying
AU  - Na, Feifei
AU  - Wu, Yijun
AU  - Kang, Kai
AU  - Xiu, Weigang
AU  - Zhang, Xuanwei
AU  - Zhou, Lin
AU  - Xu, Yong
AU  - Wang, Jin
AU  - Wang, Yan
AU  - Yang, Xue
AU  - Wu, Yuanjun
AU  - Li, Rui
AU  - Zhang, Yu
AU  - Yang, Zhenzhou
AU  - Zhou, Zhipeng
AU  - Bai, Jing
AU  - Yi, Xin
AU  - Tong, Ruizhan
AU  - Yin, Limei
AU  - Chen, Chong
AU  - Niedermann, Gabriele
AU  - Lu, You
AU  - Xue, Jianxin
TI  - Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients.
JO  - Clinical cancer research
VL  - 29
IS  - 20
SN  - 1078-0432
CY  - Philadelphia, Pa. [u.a.]
PB  - AACR
M1  - DKFZ-2023-01663
SP  - 4098-4108
PY  - 2023
N1  - 2023 Oct 13;29(20):4098-4108
AB  - Low-dose radiation therapy (LDRT) may enhance the synergistic anti-tumor effect of combined immunotherapy and stereotactic body radiation therapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the first time as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC).This prospective phase 1 study enrolled 29 patients and included a dose-escalation and dose-expansion phase. Patients received SBRT (30 Gy/3f) to small lesions and LDRT (2 Gy/1f, 4 Gy/2f, or 10 Gy/5f) to a large lesion concurrently, followed by sintilimab (a PD-1 inhibitor). The primary endpoint was safety and tolerability; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).No dose-limiting toxicities were observed during the dose-escalation phase; 4 Gy/2f was the recommended LDRT dose. Median follow-up was 15.6 months. Treatment-related adverse events (TRAEs) occurred in 96.6
LB  - PUB:(DE-HGF)16
C6  - pmid:37581611
DO  - DOI:10.1158/1078-0432.CCR-23-0315
UR  - https://inrepo02.dkfz.de/record/278582
ER  -